Details of the Drug

General Information of Drug (ID: DMKD5ZO)

Drug Name

NN-8226

Synonyms

NNC-109-0012; IL-20 monoclonal antibody (inflammation), Novo Nordisk; Anti-IL20 (inflammation), ZymoGenetics/Novo Nordisk; Anti-IL20mAb (RA), ZymoGenetics/Novo Nordisk; Anti-interleukin-20 (rheumatoid arthritis), ZymoGenetics/Novo Nordisk

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

TTD ID: D00LGA

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-20 (IL20)	TTNZMY2	IL20_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Psoriasis vulgaris

ICD Disease Classification

EA90

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin-20 (IL20)	DTT	IL20	1.82E-12	1.01	1.18

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT02097264) A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. U.S. National Institutes of Health.
2	Handbook of Therapeutic Antibodies. 2014. 1. Page(995).